Novo Nordisk plunged 27% this month—the worst monthly performance in over two decades. What challenges is the company facing?

If EFX receives regulatory approval and successfully launches, it could be used either independently or in combination with Novo Nordisk’s Wegovy (Wegovy), creating a 'game-changing' treatment regimen. It would also synergize with Novo Nordisk’s semaglutide, jointly expanding into the overlapping markets of MASH and obesity. This move is also viewed as direct competition against rivals such as Roche and Eli Lilly. Amid intensifying competition in the weight-loss drug market—and slowing growth in key markets—Novo Nordisk has begun actively pursuing self-rescue measures. Besieged on all fronts: layoffs and strategic streamlining to restart As its first-mover advantage fades, even the global leader in weight-loss medications is struggling. Founded in 1923 and headquartered in Denmark, Novo Nordisk is a leading global healthcare company. It employs approximately 78,400 people across 80 countries and sells products in 170 countries. Its Class B shares trade on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange. Impacted by intensifying market competition and recent market exits of generic drugs, Novo Nordisk’s latest quarterly financial report—released in August—showed that second-quarter growth still fell short of expectations. The company lowered its 2025 operating profit growth forecast to 4–10%, down from the prior projection of 10–16%. Notably, this marks the third time Novo Nordisk has revised its annual outlook downward this year, and its share price has declined roughly 60% from its peak. Faced with mounting internal and external pressures, the multinational giant completed a leadership transition in early August: Lars Fruergaard Jørgensen stepped down as President and CEO, and Maziar Mike Doustdar was appointed as the new President and CEO. The new CEO wasted no time—his first major initiative targeted large-scale personnel restructuring. On September 10, Novo Nordisk issued a statement announcing a company-wide reorganization plan “aimed at streamlining organizational structure, accelerating decision-making, and reallocating resources to capture growth opportunities in diabetes and obesity.” According to insiders, although this historic round of layoffs primarily affects the Danish headquarters, it also extends to China. Severance packages reportedly reach N+6, where N equals pre-tax average income—meaning many long-tenured employees may effectively retire on the spot. In addition to the large-scale layoffs, Novo Nordisk froze global hiring last month—including all positions in non-critical business units. This internal restructuring and transformation effort is expected to incur one-time restructuring costs totaling 8 billion Danish kroner (including impairment expenses); an additional 9 billion DKK in restructuring costs will arise in Q3 2025, with approximately 1 billion DKK offset in Q4. These internal 'growing pains' serve a longer-term corporate strategy: developing innovative, differentiated medicines to treat millions of patients suffering from diabetes, obesity, and related comorbidities. The new Global President’s second priority was the swift advancement of the acquisition of Akero Therapeutics. Regarding this transaction, Andrew Cheng, President and CEO of Akero, stated: "This transaction follows a comprehensive review by our Board of Directors and delivers significant value to shareholders. It also enables us to bring therapeutic options to more patients worldwide, leveraging Novo Nordisk’s industry-leading R&D and commercialization capabilities."

After posting a staggering $180 billion loss, the world’s fourth-largest automaker seeks a comeback via China’s new-energy vehicle makers.

Recently, Stellantis Group released its full-year 2025 financial results—an outcome widely anticipated to be nothing short of catastrophic: a net loss of €22.3 billion, equivalent to approximately RMB 180 billion. Roughly speaking, that amounts to nearly RMB 500 million in net losses per day last year. Among traditional automakers that have so far reported full-year results, Stellantis’ loss magnitude is now 'unrivaled globally.' Just one year earlier, the company had posted a profit of €5.52 billion. Although driven partly by non-recurring factors, persistent profit erosion and operational losses have placed this once-most-profitable automaker under severe existential threat. Coinciding with Stellantis’ earnings release, Bloomberg reported that the company is considering expanding its joint venture with Chinese EV maker Leapmotor—specifically adopting Leapmotor’s battery and electric drive technologies to reduce development costs for mainstream European brands including Fiat, Opel, and Peugeot. From 'sales collaboration' to 'technology sharing,' Stellantis is turning to enigmatic Eastern expertise. 01 Strategic divestment A full-year net loss of €22.3 billion—approximately RMB 180 billion—marks the first annual loss since Stellantis’ formation through merger. Former CEO Carlos Tavares consequently resigned in response. Behind this colossal loss lies the same core cause behind Ford’s recent annual loss: massive, one-time asset impairments triggered by strategic shifts toward electrification. Ford recorded a special-item charge of roughly $19.5 billion, resulting in a dismal $8.2 billion annual net loss. Stellantis faced a similar situation: its comprehensive strategic reset led to total one-time special expenditures amounting to €25.4 billion. Moreover, 20 days before releasing these financial results, Stellantis announced a massive €22.2 billion (approx. $26 billion) transformation-related expense. Of this sum, €14.7 billion was allocated to revising pure-electric vehicle plans and adapting to new U.S. emissions regulations—including halting production of the RAM 1500 electric pickup truck in the U.S. and delaying multiple Alfa Romeo electric vehicle projects. €2.1 billion relates to adjustments in the EV supply chain scale—for instance, Stellantis announced the divestment of its 49% stake in NextStar Energy, its Canadian battery manufacturing joint venture with LG Energy Solution, transferring full control to LG. An additional €5.4 billion covers quality remediation and layoff costs: €4.1 billion stems from revised warranty estimates due to inflation and deteriorating quality; €1.3 billion covers expenses associated with expanded layoffs across Europe. Delivering such a result was thus entirely foreseeable. Antonio Filosa, Stellantis’ newly appointed CEO, acknowledged that the 2025 full-year results reflect two key costs: "Our 2025 full-year performance reflects the cost of having overestimated the pace of the energy transition, as well as the cost of adjusting our business to enable customers to freely choose across our full portfolio of electric, hybrid, and internal-combustion engine technologies."

Kronos Worldwide Q4 Loss Widens, Net Sales Decline

May 11, 2026

Kronos Worldwide reported a widened Q4 net loss of $13.7 million, with diluted loss per share reaching $0.12. Net sales declined 8% to $468.7 million primarily due to reduced titanium dioxide sales volumes.

Moomoo

2026-04-14

Kronos Worldwide, Inc. Announces Expected First Quarter 2026 Earnings Release Date

2026-04-15

Kronos sets May 6 release for first-quarter results after close

2026-05-04

Kronos Worldwide Reports Q4 2025 Net Loss of $82.8 Million

2026-05-04

Kronos Worldwide Inc Expected to Post Loss of 22 Cents a Share - Earnings Preview

2026-05-06

Kronos Worldwide, Inc. Reports First Quarter 2026 Results